US20120115909A1 - Tazarotene derivatives - Google Patents

Tazarotene derivatives Download PDF

Info

Publication number
US20120115909A1
US20120115909A1 US13/383,869 US201013383869A US2012115909A1 US 20120115909 A1 US20120115909 A1 US 20120115909A1 US 201013383869 A US201013383869 A US 201013383869A US 2012115909 A1 US2012115909 A1 US 2012115909A1
Authority
US
United States
Prior art keywords
dimethyl
optionally substituted
ethynyl
tazarotene
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/383,869
Other languages
English (en)
Inventor
Xue Ge
Hansen Wong
Wendy Huang Chern
Hans Hofland
Michael J. Bishop
Xin Frank Cai
Alan Colborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Laboratories Inc
Original Assignee
Stiefel Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Laboratories Inc filed Critical Stiefel Laboratories Inc
Priority to US13/383,869 priority Critical patent/US20120115909A1/en
Assigned to STIEFEL LABORATORIES, INC. reassignment STIEFEL LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BISHOP, MICHAEL J., COLBORN, ALAN, CAI, XIN FRANK, GE, XUE, HOFLAND, HANS, CHERN, WENDY HUANG, WONG, HANSEN
Assigned to STIEFEL LABORATORIES, INC. reassignment STIEFEL LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BISHOP, MICHAEL J., COLBORN, ALAN, CAI, XIN FRANK, GE, XUE, HOFLAND, HANS, CHERN, WENDY HUANG, WONG, HANSEN
Publication of US20120115909A1 publication Critical patent/US20120115909A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • the present invention relates to derivatives of tazarotene.
  • Tazarotene has the chemical name: ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl nicotinate.
  • Tazarotene is a retinoid prodrug which is converted to its active form, tazarotenic acid, by rapid de-esterification in most biological systems.
  • Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family; RAR ⁇ , RAR ⁇ and RAR ⁇ , but has relative selectivity for RAR ⁇ and RAR ⁇ , and may modify gene expression.
  • RAR retinoic acid receptor
  • Allergan, Inc. market TAZORAC® (tazarotene) cream and TAZORAC® (tazarotene) gel for the treatment of acne and psoriasis.
  • retinoid or an antibiotic in combination with benzoyl peroxide is of great interest to dermatologists.
  • this presents challenges to the formulation chemist insofar as retinoids and antibiotics often readily degrade in the presence of benzoyl peroxide.
  • the active ingredients are often not mixed together until immediately before administration to the patient, or are administered at different times of the day.
  • the retinoid or antibiotic might be protected (e.g. by encapsulation) from reaction with the benzoyl peroxide, or the active ingredients may be housed in separate chambers of a dual chamber dispenser.
  • the present invention is directed to new derivatives of tazarotene that penetrate the skin and exhibit retinoid-like activity.
  • the present invention provides for a compound of general formula (I):
  • n 0 or 1
  • R 1 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted cycloalkyl group, or an optionally substituted heteroaryl group;
  • R 2 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted cycloalkyl group, or an optionally substituted heteroaryl group; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula (II):
  • R 3 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted cycloalkyl group, or an optionally substituted heteroaryl group; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
  • the present invention provides a method of treating a skin disorder in a subject, the method comprising administering a composition comprising a therapeutically effective amount of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, to a subject in need thereof.
  • the present invention relates to the use of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a skin disorder.
  • the present invention relates to the use of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, for the treatment of a skin disorder.
  • FIG. 1 illustrates the degradation of tazarotene into its degradation products when DUAC® gel and TAZORAC® cream are mixed together. The degradation was observed over 8 hours once “fresh” samples of DUAC gel and TAZORAC cream were mixed.
  • FIG. 2A illustrates the amount of tazarotene sulfoxide and tazarotenic acid in stability samples (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 2B illustrates the amount of tazarotene benzoate in stability samples (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 3A illustrates the amount of tazarotene, tazarotene sulfoxide and tazarotenic acid in the epidermis 2 hours post-application (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 3B illustrates the amount of tazarotene, tazarotene sulfoxide and tazarotenic acid in the dermis 2 hours post-application (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 4A illustrates the amount of tazarotene, tazarotene sulfoxide and tazarotenic acid in the epidermis 6 hours post-application (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 4B illustrates the amount of tazarotene, tazarotene sulfoxide and tazarotenic acid in the dermis 6 hours post-application (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 5A illustrates the amount of tazarotene benzoate in the epidermis and dermis 2 hours post-application (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 5B illustrates the amount of tazarotene benzoate in the epidermis and dermis 6 hours post-application (at least 4 replicates and 4 donors (n ⁇ 17) ⁇ SEM).
  • FIG. 6 illustrates skin penetration from mixtures of DUAC gel and TAZORAC cream.
  • the data points represent the cumulative amount of tazarotene sulfoxide from at least 4 replicates from 4 donors (n ⁇ 18) ⁇ SEM.
  • FIG. 7 illustrates pro-inflammatory cytokine (IL-1 ⁇ and IL-8) release from SkinEthic RHE cultures following exposure to various retinoids. Each bar represents the average of duplicate cultures ( ⁇ Stdev).
  • FIG. 8 illustrates the PMA-induced IL-6 release from A431 cultures following exposure to various retinoids. Each bar represents the average of triplicate cultures ( ⁇ Stdev).
  • FIG. 9 illustrates the stability of tazarotene, tazarotene sulfoxide and tazarotene benzoate in rat plasma at room temperature.
  • FIG. 10 illustrates the stability of tazarotene, tazarotene sulfoxide and tazarotene benzoate in human plasma at room temperature.
  • FIG. 11 illustrates the peak for tazarotene benzoate measured with a Shimadzu HPLC-Applied Biosystems 4000 QTRAP.
  • FIG. 12 illustrates the peak for hydroxytazarotenic acid measured with a Shimadzu HPLC-Applied Biosystems 4000 QTRAP.
  • FIG. 13 illustrates the mass spectra fragmentation of hydroxytazarotenic acid.
  • FIG. 14 illustrates the mass spectra fragmentation of tazarotenic acid sulfoxide.
  • FIG. 15 illustrates the amount of IL-1 ⁇ released in the presence of various retinoids.
  • FIG. 16 illustrates the amount of IL-8 released in the presence of various retinoids.
  • FIG. 17 illustrates the biological (retinoid) activity of various metabolites and analogues of tazarotene benzoate i.e. by determining gene expression levels for K4.
  • the respective metabolites and analogues are shown in Table 11 (labeled compounds 1 to 29).
  • FIG. 18 illustrates the biological (retinoid) activity of various metabolites and analogues of tazarotene benzoate i.e. by determining gene expression levels for K10.
  • the respective metabolites and analogues are shown in Table 11.
  • FIG. 19 illustrates the biological (retinoid) activity of various metabolites and analogues of tazarotene benzoate i.e. by determining gene expression levels for K13.
  • the respective metabolites and analogues are shown in Table 11.
  • FIG. 20 illustrates the biological (retinoid) activity of various metabolites and analogues of tazarotene benzoate i.e. by determining gene expression levels for K19.
  • the respective metabolites and analogues are shown in Table 11.
  • FIG. 21 illustrates the biological (retinoid) activity of various metabolites and analogues of tazarotene benzoate i.e. by determining gene expression levels for filaggrin.
  • the respective metabolites and analogues are shown in Table 11.
  • FIG. 22 illustrates the proposed metabolism of tazarotene.
  • FIG. 23 illustrates the proposed metabolism of tazarotene benzoate.
  • FIGS. 24A , 24 B and 24 C illustrate the enhanced stability of tazarotene benzoate and tazarotene nicotinate in the presence of benzoyl peroxide, relative to tazarotene and hydroxy tazarotenic acid.
  • the present invention provides a compound of general formula (I):
  • n 0 or 1
  • R 1 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted C 3-7 cycloalkyl group, or an optionally substituted heteroaryl group;
  • R 2 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted C 3-7 cycloalkyl group, or an optionally substituted heteroaryl group; or a pharmaceutically acceptable salt thereof.
  • n is 0 or an integer having a value of 1. In one embodiment, n is 1. In another embodiment n is 0. In one embodiment, n is 0, and R 1 is hydrogen.
  • R 1 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted C 3-7 cycloalkyl group, or an optionally substituted heteroaryl group.
  • R 2 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted C 3-7 cycloalkyl group, or an optionally substituted heteroaryl group.
  • R 1 is an optionally substituted C 1-18 alkyl, C 2-18 alkenyl, C 2-18 alkynyl, aryl, heterocyclic, cycloalkyl or heteroaryl group
  • the group is optionally substituted one or more times, preferably 1 to 4 times independently by halogen; hydroxy; NR 4 R 5 ; hydroxy substituted C 1-6 alkyl; C 1-6 alkoxy, such as methoxy or ethoxy; halosubstituted C 1-6 alkoxy, halosubstituted C 1-6 alkyl, such as CF 2 CF 2 H or CF 3 ; C 1-6 alkyl such as methyl, ethyl, isopropyl etc.; —C(O)OR 6 , or —OC(O)R 6 .
  • the optional substituents are selected from hydroxy, NR 4 R 5 , or hydroxy substituted C 1-6 alkyl, or —C(O)OR 6 .
  • R 4 and R 5 are independently selected from hydrogen or C 1-6 alkyl. In one embodiment both R 4 and R 5 are hydrogen.
  • R 6 is independently selected from hydrogen or C 1-6 alkyl. In one embodiment R 6 is C 1-6 alkyl. In another embodiment the C 1-6 alkyl is methyl.
  • R 1 or R 2 is an optionally substituted aryl group
  • the aryl is an aromatic cyclic hydrocarbon group of from 5 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings, such as naphthyl, indene or anthryl.
  • the aryl group is an optionally substituted phenyl, naphthyl or indene.
  • the R 1 aryl group is an optionally substituted phenyl or naphthyl.
  • R 1 is an optionally substituted phenyl.
  • R 1 is phenyl or hydroxy substituted phenyl.
  • the heteroaryl ring is a monocyclic five- to seven-membered unsaturated aromatic hydrocarbon ring containing at least one heteroatom selected from oxygen, nitrogen and sulfur.
  • Suitable rings include, but are not limited to, furyl, pyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, oxathiadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, or uracil.
  • the heteroaryl group may also include fused aromatic rings comprising at least one heteroatom selected from oxygen, nitrogen and sulfur.
  • fused rings contains five or six ring atoms.
  • fused aromatic rings include, but are not limited to, indolyl, isoindolyl, indazolyl, indolizinyl, azaindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, purinyl or phthalazinyl.
  • R 1 when R 1 is an optionally substituted heteroaryl group, the heteroaryl is an optionally substituted 2-, 3- or 4-pyridyl or pyranyl ring. In another embodiment the heteroaryl is an optionally substituted 2-, 3- or 4-pyridyl. In another embodiment R 1 is an optionally substituted pyrid-3-yl.
  • the heterocyclic ring is a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom selected from nitrogen, oxygen, sulphur or oxidized sulphur moieties, such as S(O)m, and m is 0 or an integer having a value of 1 or 2.
  • the heterocyclic group may also include fused rings, saturated or partially unsaturated, and wherein one of the rings may be aromatic or heteroaromatic. Each of the fused rings may have from four to seven ring atoms.
  • heterocyclyl groups include, but are not limited to, the saturated or partially saturated versions of the heteroaryl moieties as defined above, such as tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), azepine, diazepine, aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).
  • the heterocyclic is an optionally substituted piperidinyl, piperazinyl, tetrahydropyranyl or tetrahydrofuranyl ring.
  • the heterocyclic ring is an optionally substituted 2-, 3- or 4-piperidinyl.
  • the 2-, 3- or 4-piperidinyl is substituted by a C 1-6 alkyl.
  • the C 1-6 alkyl is methyl.
  • R 1 is a 4-methylpiperidin-4-yl group.
  • R 1 is an optionally substituted C 1-18 alkyl.
  • R 1 is a C 1-18 alkyl optionally substituted, independently, one or more times by hydroxy, NR 4 R 5 , C 1-6 alkoxy, or —C(O)OR 6 .
  • the C 1-18 alkyl is unsubstituted.
  • R 1 is a C 1-3 alkyl or a C 15 alkyl.
  • R 1 is a C 1-3 alkyl.
  • the C 1-18 alkyl is substituted by —C(O)OR 6 .
  • R 6 is a C 1-6 alkyl, preferably methyl.
  • R 1 is an optionally substituted C 2-18 alkenyl.
  • R 1 is an optionally substituted aryl, heteroaryl or heterocyclic group.
  • R 1 is selected from an optionally substituted C 1-18 alkyl, a C 2-18 alkenyl, optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted tetrahydropyranyl, or optionally substituted piperidinyl. In a further embodiment, R 1 is selected from an optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted tetrahydropyranyl, or optionally substituted piperidinyl group.
  • R 2 is an optionally substituted C 1-18 alkyl, C 2-18 alkenyl, C 2-18 alkynyl, aryl, heterocyclic, cycloalkyl or heteroaryl group
  • the group is optionally substituted one or more times, preferably 1 to 4 times, independently by halogen; hydroxy; NR 4 R 5 ; hydroxy substituted C 1-6 alkyl; C 1-6 alkoxy, such as methoxy or ethoxy; halosubstituted C 1-6 alkoxy; halosubstituted C 1-6 alkyl, such as CF 2 CF 2 H or CF 3 ; C 1-6 alkyl such as methyl, ethyl, isopropyl, etc.; —C(O)OR 6 or —OC(O)R 6 .
  • R 2 is hydrogen or optionally substituted C 1-18 alkyl. In an embodiment, R 2 is hydrogen or optionally substituted C 1-6 alkyl. In another embodiment, R 2 is hydrogen. In another embodiment, R 2 is C 1-6 alkyl. According to a further embodiment, R 2 is ethyl.
  • n is 1, R 1 is phenyl and R 2 is hydrogen or C 1-6 alkyl. In another embodiment, n is 1, R 1 is phenyl and R 2 is hydrogen.
  • This compound is known as 6-(2-(2-benzoyloxy-4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid, and is also described herein as tazarotenic acid benzoate.
  • n is 1, R 1 is phenyl and R 2 is C 1-6 alkyl. In one embodiment, the C 1-6 alkyl is ethyl.
  • This compound is known as 6-(2-(2-benzoyloxy-4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid, ethyl ester, and is described herein as tazarotene benzoate.
  • the compound is (S)-6-(2-(2-benzoyloxy-4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid, ethyl ester. In another embodiment, the compound is (R)-6-(2-(2-benzoyloxy-4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid, ethyl ester.
  • n 0, R 1 is hydrogen and R 2 is hydrogen or C 1-6 alkyl. In an embodiment, R 2 is hydrogen.
  • This compound is 6-((2-hydroxy-4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid, and is also described herein as hydroxy tazarotenic acid.
  • n is 0, R 1 is hydrogen and R 2 is C 1-6 alkyl.
  • C 1-6 alkyl is ethyl. This compound is ethyl 6-[(2-hydroxy-4,4-dimethyl-3,4-dihydro-2-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate, and is also described herein as hydroxy tazarotene.
  • the compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt.
  • suitable salts see Berge et al., J. Pharm. Sci., 1977, 66, 1-19.
  • a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • a compound of Formula (I) is selected from:
  • the compound of Formula (I) is 6-[4,4-dimethyl-2-(pyridine-3-carbonyloxy)thiochroman-6-ylethynyl]nicotinic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is (S)-6-[4,4-dimethyl-2-(pyridine-3-carbonyloxy)thiochroman-6-ylethynyl]nicotinic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is (R)-6-[4,4-dimethyl-2-(pyridine-3-carbonyloxy)thiochroman-6-ylethynyl]nicotinic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[2-palmitoyl-4,4-dimethyl-3,4-dihydro-2-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is 6-[2-(2-Hydroxy-acetoxy)-4,4-dimethyl-thiochroman-6-ylethynyl]-nicotinic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-(2-methoxyacetyl)-4,4-dimethyl-3,4-dihydro-2-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-acetyl-4,4-dimethyl-3,4-dihydro-2-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-n-butyryloxyl-4,4-dimethyl-3,4-dihydro-2-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-lauroyl-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-isobutyryloxy-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-linoeoyll-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-linleolyl-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-(N-methyl-4-piperidinylcarboxy-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-propionyl-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-salicylicyl-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-(4-pyranyloxy-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-monomethyladopyl-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is ethyl 6-[(2-(3-monomethylazelauate-4,4-dimethyl-3,4-dihydro-2-thiochrornen-6-yl)ethynyl]pyridine-3-carboxylate, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is 6-[2-((S)-2-Amino-3-methyl-butyryloxy)-4,4-dimethyl-thiochroman-6-ylethynyl]-nicotinic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) is selected from the group consisting of:
  • the invention provides a compound of the formula:
  • R 3 is hydrogen, optionally substituted C 1-18 alkyl, optionally substituted C 2-18 alkenyl, optionally substituted C 2-18 alkynyl, optionally substituted aryl group, optionally substituted heterocyclic group, optionally substituted C 3-7 cycloalkyl group, or an optionally substituted heteroaryl group; or a pharmaceutically acceptable salt thereof.
  • R 3 is an optionally substituted C 1-18 alkyl, C 2-18 alkenyl, C 2-18 alkynyl, aryl, heterocyclic, cycloalkyl or heteroaryl group, the group is optionally substituted one or more times, preferably 1 to 4 times independently by halogen; hydroxy; NR 4 R 5 ; hydroxy substituted C 1-6 alkyl; C 1-6 alkoxy, such as methoxy or ethoxy; halosubstituted C 1-6 alkoxy; halosubstituted C 1-6 alkyl, such as CF 2 CF 2 H or CF 3 ; C 1-6 alkyl such as methyl, ethyl, isopropyl, etc.; —C(O)OR 6 or —OC(O)R 6 .
  • R 4 and R 5 are independently selected from hydrogen or C 1-6 alkyl. In one embodiment both R 4 and R 5 are hydrogen.
  • R 6 is independently selected from hydrogen or C 1-6 alkyl. In one embodiment R 6 is C 1-6 alkyl. In another embodiment the C 1-6 alkyl is methyl.
  • R 3 is an optionally substituted aryl group, it is as defined above for R 1 or R 2 in Formula (I) herein.
  • R 3 is an optionally substituted heteroaryl group, it is as defined above for R 1 or R 2 in Formula (I) herein.
  • R 3 is an optionally substituted heterocyclic group, it is as defined above for R 1 or R 2 in Formula (I) herein.
  • R 3 is hydrogen or an optionally substituted C 1-6 alkyl.
  • R 3 is hydrogen.
  • This compound is 6-((4,4-dimethyl-2-oxothiochroman-6-yl)ethynyl)nicotinic acid, and is also described herein as keto tazarotenic acid.
  • R 3 is C 1-6 alkyl.
  • the C 1-6 alkyl is ethyl.
  • This compound is ethyl 6-((4,4-dimethyl-2-oxothiochroman-6-yl)ethynyl)nicotinate, and is also described herein as keto tazarotene.
  • the compound is 6-(2-(2-benzoyloxy-4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid, ethyl ester (i.e. tazarotene benzoate).
  • Tazarotene benzoate is formed by combining tazarotene and benzoyl peroxide. This novel compound penetrates the skin and has retinoid-like activity.
  • S and R enantiomers have been isolated and characterized, and described herein.
  • a range of analogues and metabolites of tazarotene benzoate have also been isolated, synthesized and characterized as is further described.
  • tazarotene sulfoxide and tazarotenic acid have been shown to penetrate the skin.
  • other known metabolites of tazarotene namely ethyl 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinate (tazarotene sulfone), 6-((4,4-dimethyl-1-oxidothiochroman-6-yl)ethynyl)nicotinic acid (tazarotenic acid sulfoxide), and 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinic acid (tazarotenic acid sulfone), which were previously thought by others to have little or no retinoid activity, have been discovered to exert retinoid like activity ( FIG. 22 and Example 3).
  • the present invention also relates to a method of treating a skin disorder in a subject, the method comprising administering a composition comprising a therapeutically effective amount of a compound selected from the group consisting of ethyl 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinate, 6-((4,4-dimethyl-1-oxidothiochroman-6-yl)ethynyl)nicotinic acid and 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinic acid, or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients, to a subject in need thereof.
  • a composition comprising a therapeutically effective amount of a compound selected from the group consisting of ethyl 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)e
  • the present invention relates to the use of a compound selected from the group consisting of ethyl 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinate, 6-((4,4-dimethyl-1-oxidothiochroman-6-yl)ethynyl)nicotinic acid and 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinic acid, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a skin disorder.
  • the invention relates to the use of a compound selected from the group consisting of ethyl 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinate, 6-((4,4-dimethyl-1-oxidothiochroman-6-yl)ethynyl)nicotinic acid and 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinic acid, or a pharmaceutically acceptable salt thereof, for the treatment of a skin disorder.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound selected from the group consisting of ethyl 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinate, 6-((4,4-dimethyl-1-oxidothiochroman-6-yl)ethynyl)nicotinic acid and 6-((4,4-dimethyl-1,1-dioxidothiochroman-6-yl)ethynyl)nicotinic acid, or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the pharmaceutical composition comprises a second pharmaceutically active agent.
  • the second pharmaceutically active agent is selected from the group consisting benzoyl peroxide, an antibiotic, a corticosteroid and a vitamin D analogue.
  • the second pharmaceutically active agent is benzoyl peroxide.
  • the second pharmaceutically active agent is an antibiotic, such as clindamycin or a pharmaceutically acceptable salt thereof (e.g. clindamycin phosphate).
  • the second pharmaceutically active agent is a corticosteroid.
  • Suitable corticosteroids include, but are not limited to, alclometasone dipropionate, amcinonide, beclomethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, cortisone acetate, desonide, desoximetasone, diflorasone diacetate, diflucortolone valerate, fluclorolone acetonide, flumethasone pivalate, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluprednidene acetate, flurandrenolide, flurandrenolone, fluticasone propionate, halcinonide, halobetasol propionate, hydro
  • the second pharmaceutically active agent is a vitamin D analogue.
  • suitable vitamin D analogues include, but are not limited to, calcidiol, calcitriol, calcipotriene, paricalcitol, 22-oxacolcitriol, dihydrotachysterol, calciferol, and pharmaceutically acceptable salts thereof.
  • the invention provides a pharmaceutical composition comprising a compound of Formula (I) or (II) or a pharmaceutically acceptable salt thereof and a second active agent, wherein the stability of the compound of Formula (I) or (II) is superior to the stability of tazarotene in a pharmaceutical composition comprising tazarotene and the second active agent.
  • the compound of Formula (I) or (II) is tazarotene benzoate or tazarotene nicotinate.
  • the second active agent is benzoyl peroxide.
  • the amounts present in the composition are therapeutically effective amounts for the treatment of skin disorders.
  • the compounds of the present invention may be formulated as pharmaceutical compositions and administered orally, topically, dermally, parenterally, by injection, by pulmonary or nasal delivery, sublingually, rectally or vaginally.
  • the pharmaceutical composition is adapted for oral or topical administration.
  • administered by injection includes intravenous, intraarticular, intramuscular (e.g. by depot injection where the active compounds are released slowly into the blood from the depot and carried from there to the target organs), intraperitoneal, intradermal, subcutaneous, and intrathecal injections, as well as use of infusion techniques.
  • Dermal administration may include topical or transdermal administration.
  • Transdermal administration can be accomplished by suitable patches, solutions, emulsions, suspensions, ointments, pastes, powders, foams, creams, lotions or gels as generally known in the art, specifically designed for the transdermal delivery of active agents, optionally in the presence of specific permeability enhancers.
  • topical administration can be accomplished by a solution, emulsion, suspension, ointment, paste, powder, foam, cream, lotion or gel.
  • topical administration is accomplished with an aerosol foam.
  • Exemplary pharmaceutically acceptable excipients include abrasives, acidifying agents, adhesives, adsorbents, alkalizing agents, antibacterial agents, anticaking agents, antioxidants, binding agents, buffering agents, bulking agents, chelating agents, coating agents, coloring agents, complexing agents, controlled release agents, cooling agents, detergents, diluents, dispersing agents, dissolution enhancers, emollients, emulsifying agents, emulsion stabilizers, film forming agents, gelling agents, glidants, humectants, lubricants, opacifying agents, penetration enhancers, pH adjusting agents, pigments, plasticizers, preservatives, propellants, sequestering agents, solubilizing agents, solvents, surfactants, suspending agents, thickening agents, viscosity increasing agents and wetting agents.
  • the pharmaceutical composition may be formulated using methods known in the art as immediate release, sustained release, delayed release, pulsatile release or two step release, for example.
  • the dosage of the active agent in the pharmaceutical composition will depend upon a variety of factors, including but not limited to, the activity of the active agent, the condition being treated, the nature of the pharmaceutical composition, the mode of administration and the age, body weight, general health and gender of the patient.
  • the present invention relates to a method of treating a skin disorder.
  • the method comprises administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients, to a subject in need thereof.
  • the skin disorder is acne, psoriasis, seborrhea, ichthyosis or keratosis pilaris.
  • the skin disorder is acne or psoriasis.
  • halo or “halogens” is used herein to mean the halogens, chloro, fluoro, bromo and iodo.
  • alkyl is used herein to mean an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 18 carbon atoms in the chain. A preferred embodiment is an alkyl group having from 1 to about 6 carbon atoms. Alkyl as defined herein may be optionally substituted with a designated number of substituents.
  • alkenyl is used herein to mean a hydrocarbon chain of a specified number of carbon atoms of either a straight or branched configuration and having at least one carbon-carbon double bond, which may occur at any point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, vinyl, alkyl or 2-butenyl.
  • Alkenyl as defined herein may be optionally substituted with a designated number of substituents.
  • alkynyl is used herein to mean a hydrocarbon chain of a specified number of carbon atoms of either a straight or branched configuration and having at least one carbon-carbon triple bond, which may occur at any point along the chain.
  • An example of an alkynyl is acetylene.
  • Alkynyl as defined herein may be optionally substituted with a designated number of substituents.
  • cycloalkyl is used herein to refer to cyclic radicals, such as a non-aromatic hydrocarbon ring containing a specified number of carbon atoms.
  • C 3-7 cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
  • Representative examples of “cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • aryl is used herein to mean an aromatic cyclic hydrocarbon group of from 5 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings (e.g. naphthyl or anthryl).
  • Preferred aryl groups include phenyl and naphthyl.
  • heteroaryl ring refers to a monocyclic five- to seven-membered unsaturated aromatic hydrocarbon ring containing at least one heteroatom selected from oxygen, nitrogen and sulfur.
  • heteroaryl rings include, but are not limited to, furyl, pyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, oxathiadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and uracil.
  • heteroaryl ring refers to fused aromatic rings comprising at least one heteroatom selected from oxygen, nitrogen and sulfur.
  • Each of the fused rings may contain five or six ring atoms.
  • fused aromatic rings include, but are not limited to, indolyl, isoindolyl, indazolyl, indolizinyl, azaindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, purinyl and phthalazinyl.
  • heterocyclic rings “heterocyclic moieties” and “heterocyclyl” are used herein to mean a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom selected from nitrogen, oxygen, sulphur or oxidized sulphur moieties, such as S(O)m, and m is 0 or an integer having a value of 1 or 2.
  • heterocyclic rings”, “heterocyclic moieties”, and “heterocyclyl” shall also refer to fused rings, saturated or partially unsaturated, and wherein one of the rings may be aromatic, or heteroaromatic.
  • Each of the fused rings may have from four to seven ring atoms.
  • heterocyclyl groups include, but are not limited to, the saturated or partially saturated versions of the heteroaryl moieties as defined above, such as tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), azepine, diazepine, aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” are used herein to mean a C 1-4 alkyl (as defined above) attached to an aryl, heteroaryl or heterocyclic moiety (as also defined above) unless otherwise indicated.
  • Heteroatom refers to a nitrogen, sulfur or oxygen atom, wherein the nitrogen and sulfur atoms may be optionally oxidized.
  • an “effective amount” or “an amount effective to” or a “therapeutically effective amount” of a pharmaceutically active agent or ingredient are used herein to refer to an amount of the pharmaceutically active agent sufficient to have a therapeutic effect upon administration. Effective amounts of the pharmaceutically active agent will vary with the particular condition or conditions being treated, the severity of the condition, the duration of the treatment, and the specific components of the composition being used.
  • administering and “administration” are used herein to mean any method which in sound medical practice delivers the pharmaceutical composition to a subject in such a manner as to provide a therapeutic effect.
  • prodrug is used herein to mean a compound which releases an active agent in vivo when the prodrug is administered to a subject.
  • Prodrugs of an active agent are prepared by modifying one or more functional groups present in the active agent in such a way that the modification may be cleaved in vivo to release the active compound.
  • treatment encompasses alleviation of at least one symptom thereof, a reduction in the severity thereof, or the delay, prevention or inhibition of the progression thereof. Treatment need not mean that the disorder is totally cured.
  • a useful composition herein need only to reduce the severity of the disorder, reduce the severity of symptoms associated therewith, provide improvement to a patient's quality of life, or delay, prevent or inhibit the onset of the disorder.
  • salts refers to salts that are pharmaceutically acceptable and that possess the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with acids such as, for example, acetic acid, benzoic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, glycolic acid, hydrochloric acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, sorbic acid, succinic acid, sulfuric acid, tartaric acid, naturally and synthetically derived amino acids, and mixtures thereof; or (2) salts formed when an acidic proton present in the parent compound is either (i) replaced by a metal ion e.g.
  • concentration range, percentage range or ratio range recited herein is to be understood to include concentrations, percentages or ratios of any integer within that range and fractions thereof, such as one tenth and one hundredth of an integer, unless otherwise indicated.
  • the term “optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.
  • substituted refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
  • the compounds of the Formulas (I) and (II) herein may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.
  • Cis (E) and trans (Z) isomerism may also occur.
  • the present invention includes the individual stereoisomers of the compounds of the invention and where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.
  • Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallization, chromatography or HPLC.
  • a stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as HPLC of the corresponding racemate using a suitable chiral support or by fractional crystallization of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
  • DUAC® gel 1% clindamycin and 5% benzoyl peroxide marketed by Stiefel Laboratories, Inc.
  • TAZORAC® cream 0.1% tazarotene marketed by Allergan, Inc.
  • tazarotene is susceptible to oxidative decomposition by benzoyl peroxide
  • an in vitro laboratory study was conducted wherein a mixture of DUAC gel and TAZORAC cream was prepared.
  • Samples were prepared by taking equal portions of DUAC gel and TAZORAC cream and mixing them thoroughly at room temperature with a spatula in a suitable container to form a uniform mixture. The initial samples were analyzed immediately by HPLC. The other samples were placed into an oven at 35° C. and removed for analysis after one, two, four, six and eight hours. An allowance was made for product evaporation over the course of the study.
  • FIG. 1 and Table 1 illustrate that approximately 22% of tazarotene was lost after four hours.
  • the major degradant product was tazarotene sulfoxide ( ⁇ 16% after 4 hours).
  • a previously unknown derivative was also identified, namely tazarotene benzoate, which eluted chromatographically after tazarotene and accounted for ⁇ 6.3% by weight after four hours.
  • Equal portions of DUAC gel and TAZORAC cream were dispensed into a glass vial and mixed for approximately three minutes with a metal spatula to ensure a homogenous mixture.
  • Samples of European DUAC gel and US DUAC gel were used in separate experiments. The products differ inasmuch as European DUAC gel does not contain paraben preservatives.
  • the test mixtures were then applied to the surface of split-thickness skin ( ⁇ 0.25 mm) at a dose of 15.6 mg/cm 2 and spread evenly using a positive displacement pipette.
  • the mixture of DUAC gel and TAZORAC cream in the stability samples resulted in the formation of tazarotene sulfoxide.
  • the quantity of the tazarotene sulfoxide degradant doubled from the 2 hour time point to the 6 hour time point.
  • tazarotene benzoate also formed. Again, there was a significant increase in the quantity of tazarotene benzoate present at the 6 hour time point relative to the 2 hour time point.
  • Tazarotene benzoate was detectable in all samples including the placebo ( FIGS. 5A and 5B ). The presence of tazarotene benzoate in the placebo sample suggests that endogenous benzoic acid may be present.
  • SkinEthic RHE cultures were transferred into 6-well plates containing 1.0 mL/well growth media. The cultures were equilibrated at 37° C. and the media was changed daily. The cultures were subsequently placed in 60 mm petri dishes containing 3.5 mL growth media. 6 ⁇ l aliquots of the Test Articles shown in Table 3 were applied to duplicate cultures. The cultures were incubated at 37° C. for 72 hours. At the end of the incubation period, the growth media was collected and stored at ⁇ 20° C. The tissues were cut in half and one half was placed in 10% NBF for histology, while the other half was placed in RNAlaterTM solution (Ambion).
  • interleukin-1 ⁇ (a pro-inflammatory cytokine) activity was only slightly increased in cultures treated with tazarotene, tazarotene benzoate or tazarotene metabolites compared to untreated and vehicle controls ( FIGS. 7 and 15 ).
  • interleukin-8 (IL-8) (a pro-inflammatory cytokine specific to retinoids) was significantly increased in all cultures treated with retinoids compared to untreated and vehicle treated controls, suggesting that tazarotene, tazarotene benzoate and the tazarotene metabolites have retinoid activity ( FIGS. 7 and 16 ).
  • histological profiles of cultures treated with TAZORAC cream or Retin-A Micro gel were as expected: namely, there was a decrease in keratohyalin granules (Hand E), a decrease in K10 expression in the suprabasal layers, and an increase in K19 expression in all viable cell layers, compared to untreated controls. Histological profiles for cultures treated with tazarotene, tazarotene benzoate and the tazarotene metabolites were similar to those of TAZORAC cream and Retin-A Micro gel, providing further evidence that they have retinoid activity.
  • A431 cells were purchased from ATCC(CRL-1555). Cells were seeded onto 12-well plates at a density of 250,000 cells/well and incubated for 72 hours at 37° C./5% CO 2 to allow cells to grow to confluency. Phorbol-12-myristate 13-acetate (PMA), diluted in DMSO (10 mg/mL stock), was added in a concentration of 10 ng/mL and retinoids were added in concentrations of 0.01 to 1 ⁇ g/mL from a 10 mg/mL stock solution in DMSO. Cultures were incubated for 48 hours at 37° C. At the end of the incubation period, growth media was collected and cell viability was determined using a CellTiterGlo assay kit (Promega). Concentrations of IL-6 were determined by ELISA and normalized based on cell viability.
  • PMA up regulates IL-6 expression through transactivation of the nuclear transcription factor, AP-1.
  • Retinoids such as tretinoin
  • tretinoin are known to inhibit transactivation of AP-1 via retinoic acid receptors.
  • tazarotene benzoate To further characterize tazarotene benzoate, the stability of tazarotene benzoate, tazarotene sulfoxide and tazarotene in human and rat plasma was studied.
  • Tazarotene, tazarotene sulfoxide and tazarotene benzoate were incubated at room temperature with human and rat plasma. The incubation was carried out in duplicate and samples were taken at specific time points for stability analyses (i) rat samples (0 hour, 2 hours and 4 hours) and (ii) human samples (0 hour, 2 hours, 4 hours and 8 hours). Samples were analyzed by LC-MS/MS.
  • Tazarotene Metabolism of Tazarotene, Tazarotene Sulfoxide, Tazarotenic Acid and Tazarotene Benzoate in the Presence of Human Liver Microsomes
  • Hepatic microsomal reactions were carried out in microcentrifuge tubes in the following manner. Human liver microsomes (0.5 or 1.0 mg/ml protein), Test Article (1 or 10 ⁇ M), paraoxon (0, 10 or 100 ⁇ M), NADPH regenerating system (10 mM glucose-6-phosphate, 1 unit/ml glucose-6-phosphate dehydrogenase, 1 mM NADP + ), magnesium chloride (5 mM) in 0.1M potassium phosphate buffer, pH 7.4 were incubated at 37° C. in a shaking water bath. Reactions were initiated with the addition of substrate with the exception of the zero-time incubations. The total reaction volume was 0.2 ml.
  • the reactions were incubated for 15, 30, 45 or 60 minutes, terminated with 0.2 ml ice-cold acetonitrile and then placed on ice. For zero-time incubations, ice cold acetonitrile was added to the mixture containing microsomes, along with NADPH regenerating system, magnesium chloride in phosphate buffer and the Test Article. Each time point was carried out in triplicate.
  • Control incubations were carried out with the identical incubation procedures as described above with the following exceptions. In negative control reactions, microsomes were not included. Positive control incubations for liver microsomes included an assessment of the microsomal stability of 7-ethoxycoumarin, which is quickly metabolized by CYPs in liver microsomal incubations of laboratory animals and humans. Duplicate reactions with an initial concentration of 10 ⁇ M were incubated for 0 or 30 minutes. Microsomal metabolic stability of 7-ethoxycoumarin was determined by LC-MS/MS.
  • Tazarotene sulfoxide was also rapidly metabolized in human liver microsomes (Table 8). Near-quantitative conversion to the tazarotenic acid sulfoxide was observed for 1 ⁇ M reactions as shown in the mass balance calculations. In the case of 1 ⁇ M reactions without NADPH, the percentage values of tazarotene sulfoxide converted to tazarotenic acid sulfoxide were over 100%. This is an unexpected result which may be due to ion suppression effects between standard and sample injections. For 10 ⁇ M substrate reactions, greater than 50% of the Test Article metabolized to tazarotenic acid sulfoxide.
  • tazarotenic acid sulfoxide was a major metabolite, but its levels were lower than those observed in incubations without NADPH. Only a fraction of NADPH-dependent metabolism is detected as tazarotenic acid sulfoxide. This suggests other metabolic pathways either by oxidation of tazarotene sulfoxide to its sulfone or by additional metabolism of tazarotenic acid sulfoxide to its sulfone.
  • tazarotenic acid benzoate m/z 444
  • hydroxy tazarotene m/z 368
  • hydroxy tazarotenic acid m/z 340
  • Hydroxy tazarotenic acid was identified as a major metabolite.
  • Metabolites with m/z 338 and 366 were also observed. While not bound by the proposal, it is believed that these are products following enzymatic oxidation of the thiolactol group to the thiolactone i.e. to form keto tazarotene and keto tazarotenic acid ( FIG. 23 ). In all, these findings are consistent with cleavage of both ester bonds by esterases.
  • liver microsomal enzymes including esterases
  • esterases the metabolism of tazarotene benzoate was further studied in vitro in the presence of human skin microsomes.
  • Human skin microsomes catalyzed fexofenadine formation from terfenadine (positive control), confirming drug metabolizing activity of human skin microsomes.
  • tazarotene benzoate and hydroxy tazarotenic acid metabolite concentrations were quantified by LC-MS/MS.
  • the retinoid activity of tazarotene, tazarotene benzoate, hydroxy tazarotenic acid, keto tazarotenic acid, keto tazarotene and a number of analogues of tazarotene benzoate were evaluated using the following methodology.
  • the compounds are set out in Table 11.
  • Reconstructed human epidermis (RHE) tissues were cultured in-house as previously described by Poumay et al. Briefly, polycarbonate culture inserts (12 mm diameter and 0.4 ⁇ m pore size, Millipore) were filled with 150 ⁇ L of a suspension containing approximately 5 ⁇ 10 5 primary adult human keratinocytes. The inserts received another 500 ⁇ L of keratinocyte culture media and were placed in a 6-well plate (1 insert/well) containing 2.5 mL of RHE Growth Media (Epilife media+1.5 mM CaCl 2 ). RHE cultures were incubated at 37° C. in a humidified atmosphere containing 5% CO 2 , for 24 hours.
  • RHE Reconstructed human epidermis
  • RHE cultures were exposed to the air-liquid interface by removing the RHE Growth Media from the top of the cultures, and replacing with 1.5 mL/well of RHE Growth Media containing 50 ⁇ g/mL vitamin C. Media was changed every other day until the cultures were dosed with Test Articles.
  • a stock solution of 0.1% tazarotene (2.83 mM at 99.5% purity) in OD/10% DMSO was prepared.
  • tazarotene benzoate hydroxytazarotenic acid, keto tazarotenic acid, keto tazarotene, and tazarotene nicotinate, a 10 mg/mL stock solution (in DMSO) was already prepared.
  • a 2.83 mM working solution (in octyldodecanol) was prepared. All other tested compounds were resuspended in DMSO and OD to obtain a final concentration of 2.83 mM in OD/10% DMSO.
  • the cultures were placed in 60 mm petri dishes containing 3 mL of RHE Growth Media (+VitC). Test articles (6 ⁇ l) were applied to triplicate cultures and cultures were incubated at 37° C. for 72 hours. Untreated and OD alone served as negative controls. At the end of the incubation period, the growth media was collected and stored at ⁇ 20° C.
  • FIGS. 17 to 21 The results of the analyses are shown in FIGS. 17 to 21 .
  • the compounds displayed on the X axes of FIGS. 17 to 21 correspond to the compounds set out in Table 11.
  • the compounds were ranked for their effect on each biomarker, as set out in Table 12.
  • Keratin 4 (K4) is not normally expressed in human epidermis but is known to be upregulated upon treatment with retinoids. All tazarotene derivatives caused significant upregulation of K4 (from 11-180-fold) compared to untreated and vehicle controls. Tazarotene, keto tazarotene, compound 17, compound 25 and compound 28 showed the highest increase (from 103 to 180-fold). Compound 21 and compound 19 showed the lowest upregulation with 11 and 19-fold, respectively.
  • Keratin 10 is an early differentiation marker that is normally expressed in the suprabasal layers of the viable epidermis, but is known to be downregulated upon treatment with retinoids.
  • S enantiomer of tazarotene benzoate compound 19 and compound 21, all other tazarotene derivatives caused a significant downregulation of K10 (approximately 7 ⁇ 4-fold) compared to untreated and vehicle controls.
  • the highest K10 downregulation was observed with tazarotene nicotinate, keto tazarotenic acid, and compound 24 (14 to 17-fold).
  • Keratin 13 (K13) is not normally expressed in human epidermis but is known to be upregulated upon treatment with retinoids. With the exception of compound 19 and compound 21, all tazarotene derivatives caused a significant upregulation of K13 (approximately 13 ⁇ 5-fold) compared to untreated and vehicle controls. The highest K13 upregulation was observed with compound 24 (23-fold), keto tazarotenic acid, and hydroxy tazarotene (20-fold), compound 23 and compound 27 (19-fold), compound 28 (18-fold), and compound 25 (17-fold).
  • Keratin 19 (K19) is not normally expressed in human epidermis but is known to be upregulated in all the viable layers of the epidermis upon treatment with retinoids. With the exception of compound 19 and compound 21, all other tazarotene derivatives caused a significant upregulation of K19 (approximately 23 ⁇ 11-fold) compared to untreated and vehicle controls. Tazarotene, compound 15, compound 23, compound 24 and compound 27 showed the highest increase (33 to 43-fold).
  • Filaggrin is a late-stage differentiation marker that is normally expressed in the stratum granulosum and is known to be downregulated upon treatment with retinoids.
  • S enantiomer of tazarotene benzoate keto tazarotene, compound 13, compound 17, compound 19, and compound 21, all other tazarotene derivatives caused a significant (3-100-fold) downregulation of filaggrin.
  • the highest level of filaggrin downregulation was observed with tazarotene nicotinate (100-fold), compound 24 (56-fold), keto tazarotenic acid (36-fold) and compound 27 (23-fold).
  • retinoid activity of a variety of tazarotene metabolites and derivatives were assessed by 5 biomarkers (Keratins 4, 10, 13, 19 and Filaggrin).
  • the respective compounds had unique expression profiles.
  • 13 derivatives were found to be more active than tazarotene.
  • reaction solutions of each compound were prepared at approximately 0.25 mg/mL in acetonitrile:water (6:4 by volume). Reactions were initiated by mixing equal volumes of the test solution with an approximately 12 mg/mL solution of benzoyl peroxide (BPO) in acetonitrile:water (4:1 by volume). Therefore, the reaction solution contained approximately 0.125 mg/mL of the test compound and the BPO was at a 50-fold excess by weight (i.e. at the same ratio as a product containing 0.1% tazarotene and 5% BPO). Aliquots of the reaction solutions were stored at various temperatures protected from light.
  • BPO benzoyl peroxide
  • Reactions were quenched by diluting 30 ⁇ L of the reaction solution to 50 mL with a diluent (acetonitrile:water in a ratio of 1:1 by volume) and storing the sample at 10° C. in the LC/MS sample tray or at 5° C. for storage. Duplicate samples were prepared at each time point (three at the start of the reaction) and the results were averaged together to generate a single value.
  • a diluent acetonitrile:water in a ratio of 1:1 by volume
  • tazarotene benzoate and tazarotene nicotinate were in the order of 25 times less reactive than tazarotene and hydroxy tazarotenic acid (with BPO).
  • the rate of reaction of each of the test compounds with BPO was found to be a function of temperature. The rate of reaction increased roughly by a factor of 5 at room temperature compared to 5° C. and increased a further factor of approximately 3 when the reaction temperature was increased to 35° C.
  • the reaction rates of tazarotene benzoate and tazarotene nicotinate appear to be similar at all temperatures.
  • DMAP 4-(Dimethylamino)pyridine
  • SPE Solid phase extraction
  • DCM Dichloromethane m-CPBA: 3-Chlorobenzene- carboperoxoic acid
  • DMF N,N-Dimethylformamide
  • Fmoc Fluorenylmethyloxy- carbonyl dppf: 1,1′-Bis(diphenylphosphino)-
  • NIS N-Iodosuccinimide ferrocene
  • DMSO Dimethylsulfoxide
  • HATU O-(7-Azabenzotriazol-1- yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
  • DIPEA N,N-Diisopropylethylamine
  • HBTU O-Benzotriazol-1-yl- N,N,N′,N′-tetramethyluronium hexafluorophosphate
  • DSC differential scanning HO
  • Oxalyl chloride (4.0 equivalents) was added to a solution of carboxylic acid (1.0 equivalent) in dichloromethane (DCM) while stirring, along with a catalytic amount of anhydrous dimethyl formamide (DMF). The resultant solution was refluxed at 40° C. for 2 hours. The solution was cooled, the solvent removed under vacuum, the excess oxalyl chloride removed using toluene, and the resultant acid chloride was redissolved in DCM and subsequently used for ester formation.
  • DCM dichloromethane
  • DMF dimethyl formamide
  • the acid chloride (1.6 mmol) was added to a solution of compound 14 (0.5 mmol) in DCM (5 mL) while stirring. Triethylamine (TEA) (2.7 mmol) was subsequently added and the reaction mixture was stirred overnight. The progress of the reaction was monitored by LC/MS. Upon completion of reaction, the reaction mixture was poured into water, extracted with DCM (2 ⁇ 5 mL aliquots). The organic extracts were combined and washed with water/brine and dried over anhydrous Na 2 SO 4 . The organic extract was concentrated and the crude ester was purified with an ISCO cartridge in a Companion system using an ethylacetate/heptanes solvent system (0-40%).
  • Triethylamine (0.75 mL) was added to a cooled (0° C.) solution of compound 14 (0.551 g, 1.5 mmol) in DCM (15 mL) under nitrogen, followed by the addition of benzoyl chloride (0.281 g, 2.0 mmol) in DCM (3 mL). The mixture was stirred for 1 hour at room temperature and then diluted with DCM (50 mL) and then treated with saturated NaHCO 3 solution, followed by water (30 mL) and brine (30 mL). The organic phase was extracted, dried over anhydrous Na 2 SO 4 , concentrated and purified using column chromatography (20% EtOAc/Heptanes) to obtain a colorless solid. Yield: 0.700 g (99%).
  • the S and R enantiomers of compound 4 (100 mg) were separated by HPLC using a chiral ADH column with a 10-50% gradient of isopropyl alcohol/water. UV absorbance was monitored at 340 nm. 33 mg and 27 mg of the respective enantiomers were obtained in >97% purity.
  • the stereochemistry of the enantiomers was determined using Ab Initio Vibrational Circular Dichroism (VCD) analysis.
  • the S and R enantiomers of compound 7 were separated by supercritical fluid chromatography using an OJH column (10 ⁇ 250 mm at 10 ml/min) using 15% ethanol as a modifier. UV absorbance was monitored at 254 nm. The respective enantiomers were obtained in a purity of about 96%.
  • the stereochemistry of the enantiomers was determined using Ab Initio Vibrational Circular Dichroism (VCD) analysis.
  • the bis-silylated glycolic acid was dissolved in 125 mL of dry DCM containing several drops of DMF.
  • a solution of 13.4 mL oxalyl chloride (148 mmoles, 4.5 equivalents) was added drop wise under nitrogen for 20 minutes.
  • the mixture was stirred for 4 hours at ambient temperature, then concentrated under vacuum to remove the volatiles (unreacted oxalyl chloride) to give the crude acid chloride (tert-butyldimethyl-silyloxy glycolic acid chloride) as a yellow oil.
  • the silylated intermediate was dissolved in THF (4 mL) and acetic acid (0.5 mL). The stirring mixture was treated with 1M TBAF (1 mL, 1 mmole) and stirred for 1 hour at ambient temperature. The crude reaction mixture was concentrated to an oil. The oil was treated with heptanes (5 mL) and kept cold ( ⁇ 4° C.) overnight. The resulting solid was filtered and washed with heptanes to give 130 mg (29%) of compound 15 as a white translucent solid.
  • Tazarotene was oxidized with sodium periodate in methanol/water to give the corresponding sulfoxide. After column purification it yielded 47 g (90%) of the sulfoxide, which was subjected to Pummerer rearrangement with acetic anhydride as the solvent and acylating agent to yield the desired product (42 g).
  • Ethyl 6-[(2-hydroxy-4,4-dimethyl-3,4-dihydro-2-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate (hydroxy tazarotene) was reacted with salicylic acid using EDC and HOBt. The reaction afforded the desired compound, along with a self coupled impurity. The desired product was obtained via column chromatography.
  • Tazarotene benzoate 6-(2-(2-benzoyloxy-4,4- dimethylthiochroman-6- yl) ethynyl) nicotinic acid, ethyl ester MW 471.58 Purity 98.0% 5 Tazarotene benzoate (S isomer) (S)-6-(2-(2- benzoyloxy-4,4- dimethylthiochroman- 6-yl) ethynyl) nicotinic acid, ethyl ester MW 471.58 Purity >97.0% 6 Tazarotene benzoate (R isomer) (R)-6-(2-(2- benzoyloxy-4,4- dimethylthiochroman- 6-yl) ethynyl) nico

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
US13/383,869 2009-07-16 2010-07-16 Tazarotene derivatives Abandoned US20120115909A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/383,869 US20120115909A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21379409P 2009-07-16 2009-07-16
US61213794 2009-07-16
US27225709P 2009-09-04 2009-09-04
US61272257 2009-09-04
US13/383,869 US20120115909A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives
PCT/US2010/042225 WO2011009023A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042225 A-371-Of-International WO2011009023A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/463,985 Continuation US9062037B2 (en) 2009-07-16 2014-08-20 Tazarotene derivatives
US14/464,060 Division US20140357669A1 (en) 2009-07-16 2014-08-20 Tazarotene derivatives

Publications (1)

Publication Number Publication Date
US20120115909A1 true US20120115909A1 (en) 2012-05-10

Family

ID=43449815

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/383,869 Abandoned US20120115909A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives
US14/464,060 Abandoned US20140357669A1 (en) 2009-07-16 2014-08-20 Tazarotene derivatives
US14/463,985 Expired - Fee Related US9062037B2 (en) 2009-07-16 2014-08-20 Tazarotene derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/464,060 Abandoned US20140357669A1 (en) 2009-07-16 2014-08-20 Tazarotene derivatives
US14/463,985 Expired - Fee Related US9062037B2 (en) 2009-07-16 2014-08-20 Tazarotene derivatives

Country Status (16)

Country Link
US (3) US20120115909A1 (pt)
EP (1) EP2453746A4 (pt)
JP (1) JP5635090B2 (pt)
KR (1) KR101536806B1 (pt)
CN (1) CN102595892B (pt)
AU (1) AU2010273261B2 (pt)
BR (1) BR112012001680A2 (pt)
CA (1) CA2768015C (pt)
EA (1) EA022322B1 (pt)
IL (1) IL217519A (pt)
IN (1) IN2012DN00546A (pt)
MX (1) MX2012000768A (pt)
NZ (1) NZ598240A (pt)
SG (1) SG177579A1 (pt)
WO (1) WO2011009023A1 (pt)
ZA (1) ZA201200253B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660309B2 (en) * 2011-06-24 2023-05-30 Gri Bio, Inc. Prevention and treatment of inflammatory conditions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105050D0 (en) 2011-03-25 2011-05-11 Iiaa Ltd Pharmaceutical agent
CN106918676B (zh) * 2015-12-24 2020-08-11 重庆华邦制药有限公司 分离测定他扎罗汀倍他米松乳膏中两种药物含量及有关物质的方法
WO2017152725A1 (zh) * 2016-03-11 2017-09-14 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用
CN107176945B (zh) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801593A (en) * 1979-09-13 1989-01-31 Burroughs Wellcome Co. Chemotherapeutic agents
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
WO1992006084A1 (en) 1990-10-09 1992-04-16 Allergan, Inc. Chromans and thiochromans with retinoid-like activity
JP3062248B2 (ja) 1991-02-13 2000-07-10 アラーガン、インコーポレイテッド レチノイド様生物学的活性を有する７位にフェニルエチニル置換基を有するクロマンおよびチオクロマン
JP3157523B2 (ja) 1991-03-26 2001-04-16 アラーガン、インコーポレイテッド レチノイド様生物学的活性を有する７位にヘテロアリールエチニル置換基を有するクロマンおよびチオクロマン
AU9259598A (en) * 1997-07-08 1999-02-08 Gist-Brocades B.V. Topical application of a combination of benzoyl peroxide and a second active ingredient
WO2000006118A2 (en) * 1998-07-28 2000-02-10 Bershad, Susan Short contact treatment of acne and photoaging with topical retinoids
US6048902A (en) * 1999-02-12 2000-04-11 Lebwohl; Mark G. Short contact treatment of psoriasis with topical retinoids
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
ITMI20050357A1 (it) * 2005-03-08 2006-09-09 Solmag S P A Procedimento di preparazione del tazarotene
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
MXPA06008988A (es) 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
EA200970724A1 (ru) * 2007-02-01 2010-02-26 Сол-Джел Текнолоджиз Лтд. Композиции для местного применения, содержащие пероксид и ретиноид

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660309B2 (en) * 2011-06-24 2023-05-30 Gri Bio, Inc. Prevention and treatment of inflammatory conditions

Also Published As

Publication number Publication date
KR20120056821A (ko) 2012-06-04
CN102595892A (zh) 2012-07-18
SG177579A1 (en) 2012-02-28
EA022322B1 (ru) 2015-12-30
BR112012001680A2 (pt) 2015-09-01
US20140357672A1 (en) 2014-12-04
IL217519A0 (en) 2012-02-29
IN2012DN00546A (pt) 2015-06-12
AU2010273261B2 (en) 2013-07-25
US9062037B2 (en) 2015-06-23
WO2011009023A1 (en) 2011-01-20
EP2453746A1 (en) 2012-05-23
JP2012533564A (ja) 2012-12-27
EP2453746A4 (en) 2013-04-24
EA201270176A1 (ru) 2012-08-30
NZ598240A (en) 2013-10-25
IL217519A (en) 2015-06-30
CN102595892B (zh) 2014-09-10
AU2010273261A1 (en) 2012-02-02
KR101536806B1 (ko) 2015-07-14
US20140357669A1 (en) 2014-12-04
MX2012000768A (es) 2012-02-13
CA2768015A1 (en) 2011-01-20
ZA201200253B (en) 2013-05-29
CA2768015C (en) 2016-03-15
JP5635090B2 (ja) 2014-12-03

Similar Documents

Publication Publication Date Title
US9062037B2 (en) Tazarotene derivatives
KR20100126434A (ko) 피리다진 유도체 및 피부 장애의 치료에서의 치료제로서의 그의 용도
JP6378630B2 (ja) 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子
RU2753490C2 (ru) Модуляторы ror-гамма
US11548853B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
Lin et al. Chemical Synthesis and Biological Activities of 20 S, 24 S/R-Dihydroxyvitamin D3 Epimers and Their 1α-Hydroxyl Derivatives
CN101460455B (zh) 9,10-断孕甾烷衍生物及医药品
JP2017515853A (ja) カルボキサミド誘導体
JP3508042B2 (ja) セラミド合成促進剤
TW201505660A (zh) 類神經醯胺功能賦予劑
JP2022512652A (ja) Ｐ２ｘ３拮抗薬での皮膚掻痒症の治療
EP2794603B1 (en) [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
US9981913B2 (en) Liver X receptor (LXR) modulators
AU2007316482A1 (en) Method of treating asthma, allergic rhinitis, and skin disorders
WO2018022797A1 (en) Dermatological formulations of 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate
Hu et al. Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
US9408793B2 (en) Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions
JP2020535169A (ja) トリメトキシフェニル化合物を含む脂肪細胞の分化又はアディポネクチンの生成促進用組成物
AU2012216754B2 (en) Phenoxy-pyrrolidine derivative and its use and compositions
WO2017094743A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する医薬組成物
WO2014162106A1 (fr) Nouveaux derives de chalcone presentant une activite anti-allergique

Legal Events

Date Code Title Description
AS Assignment

Owner name: STIEFEL LABORATORIES, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GE, XUE;WONG, HANSEN;CHERN, WENDY HUANG;AND OTHERS;SIGNING DATES FROM 20101004 TO 20110119;REEL/FRAME:025807/0355

AS Assignment

Owner name: STIEFEL LABORATORIES, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GE, XUE;WONG, HANSEN;CHERN, WENDY HUANG;AND OTHERS;SIGNING DATES FROM 20101004 TO 20110119;REEL/FRAME:027528/0908

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE